A Response to: Letter to the Editor Regarding “Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults” DOI Creative Commons

Mihaela Georgieva,

Tianyu Sun, Ekkehard Beck

и другие.

Infectious Diseases and Therapy, Год журнала: 2024, Номер 13(11), С. 2457 - 2459

Опубликована: Сен. 18, 2024

Язык: Английский

Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study DOI Creative Commons
Jennifer K Quint, Sabada Dube,

Lucy Carty

и другие.

Journal of Infection, Год журнала: 2025, Номер 90(3), С. 106432 - 106432

Опубликована: Янв. 31, 2025

Язык: Английский

Процитировано

2
Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review DOI Creative Commons

Manuela H Gschwend,

Anthony M. Marchese, Dirk Poelaert

и другие.

Vaccine, Год журнала: 2025, Номер 49, С. 126777 - 126777

Опубликована: Янв. 31, 2025

Язык: Английский

Процитировано

1
Letter to the Editor Regarding: “Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults” DOI Creative Commons
Hinpetch Daungsupawong, Viroj Wiwanitkit

Infectious Diseases and Therapy, Год журнала: 2024, Номер 13(11), С. 2455 - 2456

Опубликована: Сен. 18, 2024

Язык: Английский

Процитировано

0
A Response to: Letter to the Editor Regarding “Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults” DOI Creative Commons

Mihaela Georgieva,

Tianyu Sun, Ekkehard Beck

и другие.

Infectious Diseases and Therapy, Год журнала: 2024, Номер 13(11), С. 2457 - 2459

Опубликована: Сен. 18, 2024

Язык: Английский

Процитировано

0